US FDA approves first mRNA flu shot from Moderna

The US FDA has officially approved the first messenger RNA-based vaccine for seasonal flu, developed by the drugmaker Moderna. This regulatory milestone marks the first time an mRNA flu shot has been authorized for use in the United States. The specific approval granted by the Food and Drug Administration is intended for individuals aged 50 and older, introducing a new technological approach to combating the seasonal flu virus within this specific adult demographic group.